Metabolic effects of sulforaphane oral treatment in streptozotocin-diabetic rats

Journal of Medicinal Food

Volumn 15, Issue 9, 2012, Pages 795-801

  De Souza, Carolina Guerini ^a,b   Sattler, José Augusto ^a   De Assis, Adriano Martimbianco ^a   Rech, Anderson ^a   Perry, Marcos Luiz Santos ^a   Souza, Diogo Onofre ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

diabetes mellitus; streptozotocin; sulforaphane

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; GLUCOSE; GLYCOGEN; SULFORAPHANE; TRIACYLGLYCEROL; UREA;

ADIPOSE TISSUE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET RESTRICTION; DRUG EFFECT; DRUG SCREENING; FEEDING; GLUCOSE BLOOD LEVEL; INSULIN SENSITIVITY; LIVER FUNCTION; MALE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL;

ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIETARY SUPPLEMENTS; GLUCOSE; HEPATIC INSUFFICIENCY; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIVER; LIVER GLYCOGEN; MALE; MUSCLE, SKELETAL; RANDOM ALLOCATION; RATS; RATS, WISTAR; STREPTOZOCIN; THIOCYANATES;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84865689653     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2012.0016     Document Type: Article

References (43)

1. DeFronzo RA: From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795.
2. Third report of the national cholesterol education program (ncep): Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143-3421.
3. Chapman MJ: Metabolic syndrome and type 2 diabetes: lipid and physiological consequences. Diab Vasc Dis Res 2007;4 (Suppl 3):S5-S8. (Pubitemid 350013470)
4. Nacci C, Tarquinio M, Montagnani M: Molecular and clinical aspects of endothelial dysfunction in diabetes. Intern Emerg Med 2009;4:107-116.
5. Bourdel-Marchasson I, Lapre E, Laksir H, Puget E: Insulin resistance, diabetes and cognitive function: consequences for preventative strategies. Diabetes Metab 2010;36:173-181.
6. Merzouk S, Hichami A, Sari A, Madani S, Habane SN, Khan NA: Impaired oxidant/antioxidant status and LDL-fatty acid composition are associated with increased susceptibility to peroxidation of LDL in diabetic patients. Gen Physiol Biophys 2004;23:387-399. (Pubitemid 40352620)
7. Adiels M, Olofsson SO, Taskinem MR, Boren J: Diabetic dyslipidaemia. Curr Opin Lipidol 2006;17:238-246. (Pubitemid 43786057)
8. Martin A, Sven-Olof O, Marja RT, Jan B: Diabetic dyslipidaemia. Curr Opin Lipidol 2006;17:238-246.
9. Seetharam YN, Chalageri G, Setty SR, Bheemachar: Hypoglycaemic activity of Abutilon indicum leaf extracts in rats. Fitoterapia 2002;73:156-159. (Pubitemid 34326387)
10. Lapidot TM, Walker MD, Kanner J: Antioxidant and prooxidant effects of phenolics on pancreatic beta-cells in vitro. J Agric Food Chem 2002;50:7220-7225. (Pubitemid 35424880)
11. Coskun O, Kanter M, Korkmaz A, Oter S: Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin induced oxidative stress and beta-cell damage in rat pancreas. Pharmacol Res 2005;51:117-123. (Pubitemid 40040541)
12. Fahey JW, Talalay P: Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol 1999;37:973-979. (Pubitemid 29481800)
13. Xue M, Qian Q, Adaikalakoteswari A, Rabbani N, Babaei-Jadidi R, Thornalley PJ: Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 2008;57:2809- 2817.
14. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S: Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide array. Cancer Res 2002;62:5196-5203. (Pubitemid 35033454)
15. Zhang Y, Kensler TW, Cho CG, Posner GH, Talalay P: Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA 1994;91:3147-3150. (Pubitemid 24130192)
16. Clarke JD, Dashwood RH, Ho E: Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 2008;269:291-204.
17. Nishikawa T, Tsuno NH, Okaji Y, Shuno Y, Sasaki K, Hongo K, Sunami E, Kitayama J, Takahashi K, Nagawa H: Inhibition of autophagy potentiates sulforaphane-induced apoptosis in human colon cancer cells. Ann Surg Oncol 2010;17:592-602.
18. Song MY, Kim EK, Moon WS, Park JW, Kim HJ, So HS, Park R, Kwon KB, Park BH: Sulforaphane protects against cytokineand streptozotocin-induced beta-cell damage by suppressing the NF-kappaB pathway. Toxicol Appl Pharmacol 2009;235:57-67.
19. Danilov CA, Chandrasekaran K, Racz J, Soane L, Zielke C, Fiskum G: Sulforaphane protects astrocytes against oxidative stress and delayed death caused by oxygen and glucose deprivation. Glia 2009;57:645-656.
20. Fernandes AA, Novelli EL, Okoshi K, Okoshi MP, Di Muzio BP, Guimaraes JF, Fernandes Junior A: Influence of rutin treatment on biochemical alterations in experimental diabetes. Biomed Pharmacother 2010;64:214-219.
21. Krisman CR: A method for calorimetric estimation of glycogen with iodine. Anal Biochem 1962;4:17-23.
22. Mori MD, Baviera AM, Ramalho LTO, Vendramini RC, Brunetti IL, Pepato MT: Temporal response pattern of biochemical analytes in experimental diabetes. Biotechnol Appl Biochem 2003;38:183-191. (Pubitemid 37289834)
23. Fritsche L, Weigert C, Haring HU, Lehmann R: How insulin receptor substrate proteins regulate the metabolic capacity of the liver - implications for health and disease. Curr Med Chem 2008;15:1316-1329. (Pubitemid 351997801)
24. Bolza'n AD, Bianchi MS: Genotoxicity of streptozotocin. Mutat Res 2002;512:121-34. (Pubitemid 35441051)
25. Tesch GH, Allen TJ: Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 2007;12:261-266. (Pubitemid 46718209)
26. American Diabetes Association: Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(Suppl 1):S11-S61.
27. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(Suppl 1):S62-S69.
28. Lager I: The insulin-antagonistic effect of the counterregulatory hormones. J Intern Med Suppl 1991;735:41-47.
29. Shamoon H: Pathophysiology of diabetes. A review of selected recent developments and their impact on treatment. Drugs 1992;44(Suppl 3):1-12.
30. Noori N, Kopple JD: Effect of diabetes mellitus on protein-energy wasting and protein wasting in end-stage renal disease. Semin Dial 2010;23:178-184.
31. Hers HG: The control glycogen metabolism in the liver. Rev Biochem 1976;45:167-189.
32. Wittenstein B, Klein M, Finckh B, Ullrich K, Kohlschutter A: Plasma antioxidants in pediatric patients with glycogen storage disease, diabetes mellitus, and hypercholesterolemia. Free Radic Biol Med 2002;33:103-110. (Pubitemid 34681012)
33. Jung UJ, Lee MK, Jeong KS, Choi MS: The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/Ksj-db/db mice. J Nutr 2004;134:2499-2503. (Pubitemid 39315245)
34. Gupta S, Sharma SB, Singh UR, Bansal SK, Prabhu KM: Elucidation of mechanism of action of Cassia auriculata leaf extract for its antidiabetic activity in streptozotocin-induced diabetic rats. J Med Food 2010;13:528-534.
35. Li M, Wei D, Ding W, Baruah B, Crans DC: Anti-diabetic effects of cesium aqua (N,N'-ethylene(salicylideneiminato)-5-sulfonato) oxovanadium (IV) dihydrate in streptozotocin-induced diabetic rats. Biol Trace Elem Res 2008;121:226-232.
36. Abdulrazaq NB, Cho MM, Win NN, Zaman R, Rahman MT: Beneficial effects of ginger (Zingiber officinale) on carbohydrate metabolism in streptozotocin- induced diabetic rats. Br J Nutr 2011;12:1-8.
37. Cherng JY, Shih MF: Improving glycogenesis in Streptozocin (STZ) diabetic mice after administration of green algae Chlorella. Life Sci 2006;78:1181-1186.
38. Takada J, Machado MA, Peres SB, Brito LC, Borges-Silva CN, Costa CE, Fonseca-Alaniz MH, Andreotti S, Lima FB: Neonatal streptozotocin-induced diabetes mellitus: a model of insulin resistance associated with loss of adipose mass. Metabolism 2007;56:977-984. (Pubitemid 46890982)
39. Cameron-Smith D, Habito R, Barnett M, Collier GR: Dietary guar gum improves insulin sensitivity in streptozotocin-induced diabetic rats. J Nutr 1997;127:359-364. (Pubitemid 27079969)
40. Singh S, Dhingra S, Ramdath DD, Vasdev S, Gill V, Singal PK: Risk factors preceding type 2 diabetes and cardiomyopathy. J Cardiovasc Transl Res 2010;3:580-596.
41. Arkkila PE, Koskinen PJ, Kantola IM, Viikari JS: Diabetic complications are associated with liver enzyme activities in people with type 1 diabetes. Diabetes Res Clin Pract 2001; 52:113-118. (Pubitemid 32335604)
42. Hou JW, Chou SP, Wang TR: Metabolic function and liver histopathology in Reye-like illnesses. Acta Paediatr 1996;85: 1053-1057.
43. Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, Fang D, Zhang DD: Therapeutic potential of Nrf2 activators in streptozotocin- induced diabetic nephropathy. Diabetes 2011;60:3055-3066.